Orion OYJ (OTCMKTS:ORINY) Shares Gap Up – Time to Buy?

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $33.6250, but opened at $35.15. Orion OYJ shares last traded at $35.15, with a volume of 233 shares trading hands.

Analyst Ratings Changes

ORINY has been the topic of several recent research reports. Zacks Research lowered Orion OYJ from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 8th. Nordea Equity Research upgraded Orion OYJ from a “hold” rating to a “buy” rating in a report on Monday, October 6th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Orion OYJ has an average rating of “Moderate Buy”.

Orion OYJ Price Performance

The company has a current ratio of 1.99, a quick ratio of 1.19 and a debt-to-equity ratio of 0.13. The firm has a market cap of $9.92 billion, a price-to-earnings ratio of 28.35 and a beta of 0.04. The company has a 50 day moving average of $36.43 and a 200 day moving average of $37.30.

Orion OYJ (OTCMKTS:ORINY) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.40 earnings per share (EPS) for the quarter. The company had revenue of $494.69 million during the quarter. Orion OYJ had a return on equity of 31.36% and a net margin of 19.33%. Equities research analysts predict that Orion OYJ Unsponsored ADR will post 1.18 EPS for the current fiscal year.

Orion OYJ Announces Dividend

The business also recently announced a dividend, which was paid on Friday, November 7th. Shareholders of record on Friday, October 17th were issued a dividend of $0.2418 per share. This represents a yield of 127.0%. The ex-dividend date was Thursday, October 16th. Orion OYJ’s dividend payout ratio (DPR) is 26.61%.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.